Zheng Quanxin, Kim Ji Yoon, Cho Soo-Jeong, Kim Sang Gyun, Chung Hyunsoo
Department of Medicine, Seoul National University Graduate School, Seoul, Korea.
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Gut Liver. 2025 Mar 15;19(2):189-197. doi: 10.5009/gnl240272. Epub 2025 Jan 3.
BACKGROUND/AIMS: Gastric neuroendocrine tumors (GNETs), once rare, have become more prevalent due to the increased use of endoscopy and increased physician awareness. The clinical characteristics and long-term outcomes of GNET management were explored in this study.
The clinical data of 69 patients who treated at Seoul National University Hospital between January 2013 and October 2023 were retrospectively studied. Baseline characteristics, recurrence rates, associated factors, and overall survival rates were analyzed.
Of the tumors, 71.0% were grade 1, 24.6% were grade 2, 1.4% were grade 3, and 2.9% were poorly differentiated. In terms of tumor type, 69.6% were type I, 1.4% were type II, and 29.0% were type III. A significant proportion of patients with grade 1 tumors received more endoscopic treatment, whereas a significant proportion of patients with grade 2 tumors underwent surgery or chemotherapy (p=0.015). The overall 5-year survival and recurrence rates were 93.8% and 7.25% (5/69), respectively. Among five patients who experienced recurrence, three had metachronous recurrence, all of which were type I; the remaining two patients exhibited distant hepatic metastasis, encompassing types I and III. The time to recurrence was 1 to 9.8 years. Margin positivity (p=0.002) and invasion deeper than the submucosal layer (p=0.007) were associated with higher recurrence rates. However, there was no significant association between recurrence and intestinal metaplasia, atrophic gastritis, or Helicobacter pylori infection.
Most patients with GNETs in this study had grade I and type I tumors, and the overall prognosis was favorable. Patients with risk factors for recurrence warrant further investigation. Those presenting margin positivity or deep invasion after resection should be closely monitored and undergo follow-up examinations, as necessary.
背景/目的:胃神经内分泌肿瘤(GNETs)曾较为罕见,但由于内镜检查的使用增加以及医生意识的提高,其发病率已变得更高。本研究探讨了GNETs治疗的临床特征和长期预后。
回顾性研究了2013年1月至2023年10月在首尔国立大学医院接受治疗的69例患者的临床资料。分析了基线特征、复发率、相关因素和总生存率。
在这些肿瘤中,71.0%为1级,24.6%为2级,1.4%为3级,2.9%为低分化。就肿瘤类型而言,69.6%为I型,1.4%为II型,29.0%为III型。相当一部分1级肿瘤患者接受了更多的内镜治疗,而相当一部分2级肿瘤患者接受了手术或化疗(p = 0.015)。总体5年生存率和复发率分别为93.8%和7.25%(5/69)。在经历复发的5例患者中,3例为异时性复发,均为I型;其余2例患者表现为远处肝转移,包括I型和III型。复发时间为1至9.8年。切缘阳性(p = 0.002)和浸润深度超过黏膜下层(p = 0.007)与较高的复发率相关。然而,复发与肠化生、萎缩性胃炎或幽门螺杆菌感染之间无显著关联。
本研究中大多数GNETs患者为I级和I型肿瘤,总体预后良好。有复发危险因素的患者需要进一步研究。切除后出现切缘阳性或深度浸润的患者应密切监测,并根据需要进行随访检查。